Biodexa Pharmaceuticals (BDRX) Beginning Cash Balance (2019 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Beginning Cash Balance of $11.8 million for Q4 2022, down 5.16% sequentially from $12.4 million in Q3 2022, and up 15.97% YoY from $10.2 million in Q4 2021.
Biodexa Pharmaceuticals (BDRX) Beginning Cash Balance (2019 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Beginning Cash Balance for 4 years, with the latest figure at $11.8 million in Q4 2022.
- Quarterly Beginning Cash Balance rose 15.97% year-over-year to $11.8 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $44.9 million (down 8.1% YoY) and the FY2022 annual result came in at $12.4 million, up 19.88% from the prior year.
- Beginning Cash Balance slipped to $11.8 million in Q4 2022 per BDRX's latest filing, from $12.4 million in the prior quarter.
- Over five years, Beginning Cash Balance peaked at $14.4 million in Q4 2020 and troughed at $3.0 million in Q4 2019.
- A 4-year average of $10.9 million and a median of $11.8 million in 2022 frame the typical range for Beginning Cash Balance.
- The sharpest annual moves came in 2020 and 2021: Beginning Cash Balance soared 379.01% in 2020, then fell 29.51% in 2021.
- Over 4 years, Beginning Cash Balance stood at $3.0 million in 2019, then jumped by 379.01% to $14.4 million in 2020, then retreated by 29.51% to $10.2 million in 2021, then climbed by 15.97% to $11.8 million in 2022.
- According to Business Quant data, Beginning Cash Balance over the past three periods registered $11.8 million, $12.4 million, and $10.2 million for Q4 2022, Q3 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.23 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Jun 30, 2024 | 7.54 Mn |
| Jun 30, 2024 | 7.54 Mn |
| Jun 30, 2023 | 3.55 Mn |
| Jun 30, 2023 | 3.55 Mn |
| Dec 31, 2022 | 11.80 Mn |
| Dec 31, 2022 | 11.80 Mn |
| Sep 14, 2022 | 12.44 Mn |
| Sep 14, 2022 | 12.44 Mn |
| Dec 31, 2021 | 10.17 Mn |
| Dec 31, 2021 | 10.17 Mn |
| Sep 17, 2021 | 10.49 Mn |
| Sep 17, 2021 | 10.49 Mn |
| Dec 31, 2020 | 14.43 Mn |
| Dec 31, 2020 | 14.43 Mn |
| Sep 10, 2020 | 13.76 Mn |
| Sep 10, 2020 | 13.76 Mn |
| Dec 31, 2019 | 3.01 Mn |
| Dec 31, 2019 | 3.01 Mn |